A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer

BACKGROUND: Immune checkpoint blockade (ICB) therapy has brought remarkable clinical benefits to patients with advanced non-small cell lung carcinoma (NSCLC). However, the prognosis remains largely variable. METHODS: The profiles of immune-related genes for patients with NSCLC were extracted from TC...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Shuai, Jiang, Dongjie, Zhang, Feng, Li, Kun, Jiao, Kun, Hu, Jingyun, Song, Haihan, Ma, Qin-Yun, Wang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924230/
https://www.ncbi.nlm.nih.gov/pubmed/36793597
http://dx.doi.org/10.3389/fonc.2023.1095313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924230/
https://www.ncbi.nlm.nih.gov/pubmed/36793597
http://dx.doi.org/10.3389/fonc.2023.1095313

Ejemplares similares